27940576|t|Aspirin Suppresses Growth in PI3K - Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling
27940576|a|Despite the high incidence of oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of PI3K, PI3K inhibitors have yielded little clinical benefit for breast cancer patients. Recent epidemiologic studies have suggested a therapeutic benefit from aspirin intake in cancers harboring oncogenic PIK3CA Here, we show that mutant PIK3CA - expressing breast cancer cells have greater sensitivity to aspirin -mediated growth suppression than their wild-type counterparts. Aspirin decreased viability and anchorage-independent growth of mutant PIK3CA breast cancer cells independently of its effects on COX-2 and NF-κB. We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activation, mTORC1 inhibition, and autophagy induction. In vivo, oncogenic PIK3CA -driven mouse mammary tumors treated daily with aspirin resulted in decreased tumor growth kinetics, whereas combination therapy of aspirin and a PI3K inhibitor further attenuated tumor growth. Our study supports the evaluation of aspirin and PI3K pathway inhibitors as a combination therapy for targeting breast cancer. Cancer Res; 77(3); 790-801. ©2016 AACR.
27940576	0	7	Aspirin	T103	UMLS:C0004057
27940576	19	25	Growth	T038	UMLS:C0018270
27940576	29	33	PI3K	T017	UMLS:C1335212
27940576	36	42	Mutant	T017	UMLS:C0678941
27940576	43	56	Breast Cancer	T038	UMLS:C0678222
27940576	71	75	AMPK	T103	UMLS:C2350345
27940576	91	97	mTORC1	T103	UMLS:C2975458
27940576	138	147	oncogenic	T017	UMLS:C0029016
27940576	148	157	mutations	T038	UMLS:C0026882
27940576	161	167	PIK3CA	T017	UMLS:C1335212
27940576	173	186	gene encoding	T017	UMLS:C3839127
27940576	191	208	catalytic subunit	T082	UMLS:C0600499
27940576	212	216	PI3K	T103	UMLS:C0044602
27940576	218	222	PI3K	T103	UMLS:C0044602
27940576	223	233	inhibitors	T103	UMLS:C0014432
27940576	254	270	clinical benefit	T033	UMLS:C1333602
27940576	275	288	breast cancer	T038	UMLS:C0678222
27940576	306	327	epidemiologic studies	T062	UMLS:C0002783
27940576	370	377	aspirin	T103	UMLS:C0004057
27940576	388	395	cancers	T038	UMLS:C0006826
27940576	406	422	oncogenic PIK3CA	T103	UMLS:C0044602
27940576	442	448	mutant	T017	UMLS:C0678941
27940576	449	455	PIK3CA	T103	UMLS:C0044602
27940576	458	468	expressing	T038	UMLS:C0017262
27940576	469	488	breast cancer cells	T017	UMLS:C1512505
27940576	517	524	aspirin	T103	UMLS:C0004057
27940576	535	541	growth	T038	UMLS:C0007595
27940576	542	553	suppression	T038	UMLS:C0007613
27940576	565	574	wild-type	T017	UMLS:C1883559
27940576	589	596	Aspirin	T103	UMLS:C0004057
27940576	607	616	viability	T038	UMLS:C0007620
27940576	621	649	anchorage-independent growth	T058	UMLS:C1515979
27940576	653	659	mutant	T017	UMLS:C0678941
27940576	660	666	PIK3CA	T103	UMLS:C0044602
27940576	667	686	breast cancer cells	T017	UMLS:C1512505
27940576	687	700	independently	T033	UMLS:C1299583
27940576	719	724	COX-2	T103	UMLS:C0387583
27940576	729	734	NF-κB	T103	UMLS:C0079904
27940576	763	770	aspirin	T103	UMLS:C0004057
27940576	774	802	AMP-activated protein kinase	T103	UMLS:C2350345
27940576	804	808	AMPK	T103	UMLS:C2350345
27940576	822	828	mTORC1	T103	UMLS:C2975459
27940576	829	839	inhibition	T038	UMLS:C1519312
27940576	845	854	autophagy	T038	UMLS:C0004391
27940576	875	884	oncogenic	T017	UMLS:C0029016
27940576	885	891	PIK3CA	T103	UMLS:C0044602
27940576	900	905	mouse	T204	UMLS:C0025929
27940576	906	920	mammary tumors	T038	UMLS:C1458155
27940576	940	947	aspirin	T103	UMLS:C0004057
27940576	1013	1020	therapy	T058	UMLS:C0087111
27940576	1024	1031	aspirin	T103	UMLS:C0004057
27940576	1038	1042	PI3K	T103	UMLS:C0044602
27940576	1109	1119	evaluation	T058	UMLS:C0220825
27940576	1123	1130	aspirin	T103	UMLS:C0004057
27940576	1135	1139	PI3K	T103	UMLS:C0044602
27940576	1148	1158	inhibitors	T103	UMLS:C1254351
27940576	1176	1183	therapy	T058	UMLS:C0087111
27940576	1198	1211	breast cancer	T038	UMLS:C0678222